Enovis (LTS:0I1B) Inventories, Finished Goods : $484 Mil (As of Dec. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Enovis Inventories, Finished Goods?

Enovis's quarterly finished goods declined from Jun. 2024 ($541 Mil) to Sep. 2024 ($536 Mil) and declined from Sep. 2024 ($536 Mil) to Dec. 2024 ($484 Mil).

Enovis's annual finished goods increased from Dec. 2022 ($357 Mil) to Dec. 2023 ($407 Mil) and increased from Dec. 2023 ($407 Mil) to Dec. 2024 ($484 Mil).

Enovis Inventories, Finished Goods Historical Data

The historical data trend for Enovis's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enovis Inventories, Finished Goods Chart

Enovis Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Inventories, Finished Goods

Get a 7-Day Free Trial

412.82

298.45

357.14

406.93

483.58

Enovis Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Inventories, Finished Goods	Get a 7-Day Free Trial															406.93	528.68	540.75	536.33	483.58

Enovis Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.

Enovis Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Enovis Corp (LTS:0I1B) » Definitions » Inventories, Finished Goods

Comparable Companies

Traded in Other Exchanges

ENOV:USA C520:Germany

Address

2711 Centerville Road, Suite 400, Wilmington, DE, USA, 19808

Website

https://www.enovis.com

Enovis Corp is a medical technology company that offers medical devices and services across the continuum of patient care, from injury prevention to joint replacement to rehabilitation after surgery, injury, or degenerative disease. Its reportable segments are Prevention & Recovery (P&R) and Reconstructive (Recon). The company generates the maximum revenue from the Prevention & Recovery segment, which includes products that are used to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports-related injuries. The Reconstructive segment provides a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and surgical productivity tools. Geographically, it derives key revenue from the U.S.

Enovis Headlines

No Headlines